Martin Shkreli Net Worth
Martin Shkreli net worth: Martin Shkreli is an Albanian American entrepreneur and hedge fund manager who had a peak net worth of $70 million dollars. The majority of that net worth, according to Martin's own legal team, came from his stake in the company he launched, Turin Pharmaceuticals. Martin's stake in Turin was at one point worth $50 million. By March of 2018, Martin's net worth had dropped to $8 million. At this point, a judge in his criminal trial ordered him to forfeit $5 million from his ETrade account and $2.36 million worth of other assets including a Pablo Picasso painting and an unreleased Wu-Tang Clan album. Martin Shkreli was born in April 1983. He is the co-founder of MSMB Capital Management and the founder of Turing Pharmaceuticals AG. Shkreli is also the co-founder of Retrophin LLC which is a biotechnology firm. He has been criticized for obtaining manufacturing licenses for out of patent lifesaving medicines including pyrimethamine (Daraprim) and increasing the prices of those drugs in the United States. Shkreli was the executive chairman of Turing Pharmaceuticals and raised the price of Daraprim from $13.50 a pill to $750 after he purchased the rights to the drug from Impax Laboratories for $55 million. He is a League of Legends player and expressed interest in purchasing an esports team for $1.2 million in 2014 but was denied. Shkreli has also been criticized by Citizens for Responsibility and Ethics in Washington as they claim he has manipulated the US Food and Drug Administration's regulatory process to move stock prices for his own gain and sued him for $65 million in August 2015.